Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

Saved in:
Bibliographic Details
Main Authors: Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Blood Neoplasia
Online Access:http://www.sciencedirect.com/science/article/pii/S2950328025000172
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849763568977707008
author Katie Erdos
Aya Alshareef
Richard T. Silver
Joseph M. Scandura
Ghaith Abu-Zeinah
author_facet Katie Erdos
Aya Alshareef
Richard T. Silver
Joseph M. Scandura
Ghaith Abu-Zeinah
author_sort Katie Erdos
collection DOAJ
format Article
id doaj-art-52e5c70cdb5e4fd282adce20af818a79
institution DOAJ
issn 2950-3280
language English
publishDate 2025-05-01
publisher Elsevier
record_format Article
series Blood Neoplasia
spelling doaj-art-52e5c70cdb5e4fd282adce20af818a792025-08-20T03:05:22ZengElsevierBlood Neoplasia2950-32802025-05-012210008210.1016/j.bneo.2025.100082Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosisKatie Erdos0Aya Alshareef1Richard T. Silver2Joseph M. Scandura3Ghaith Abu-Zeinah4Richard T. Silver, M.D. Myeloproliferative Neoplasm Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NYWeill Cornell Medicine-Qatar, Doha, QatarRichard T. Silver, M.D. Myeloproliferative Neoplasm Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NYRichard T. Silver, M.D. Myeloproliferative Neoplasm Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NYRichard T. Silver, M.D. Myeloproliferative Neoplasm Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY; Correspondence: Ghaith Abu-Zeinah, Division of Hematology and Medical Oncology, Weill Cornell Medicine, 1300 York Ave, Box 113, New York, NY 10065;http://www.sciencedirect.com/science/article/pii/S2950328025000172
spellingShingle Katie Erdos
Aya Alshareef
Richard T. Silver
Joseph M. Scandura
Ghaith Abu-Zeinah
Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis
Blood Neoplasia
title Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis
title_full Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis
title_fullStr Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis
title_full_unstemmed Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis
title_short Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis
title_sort outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis
url http://www.sciencedirect.com/science/article/pii/S2950328025000172
work_keys_str_mv AT katieerdos outcomesforruxolitinibonlyversuscombinationwithinterferonintreatingpatientswithmyelofibrosis
AT ayaalshareef outcomesforruxolitinibonlyversuscombinationwithinterferonintreatingpatientswithmyelofibrosis
AT richardtsilver outcomesforruxolitinibonlyversuscombinationwithinterferonintreatingpatientswithmyelofibrosis
AT josephmscandura outcomesforruxolitinibonlyversuscombinationwithinterferonintreatingpatientswithmyelofibrosis
AT ghaithabuzeinah outcomesforruxolitinibonlyversuscombinationwithinterferonintreatingpatientswithmyelofibrosis